Maintenance of Crohn's disease over 12 months: fixed versus flexible dosing regimen using budesonide controlled ileal release capsules

Citation
Jrb. Green et al., Maintenance of Crohn's disease over 12 months: fixed versus flexible dosing regimen using budesonide controlled ileal release capsules, ALIM PHARM, 15(9), 2001, pp. 1331-1341
Citations number
10
Language
INGLESE
art.tipo
Article
Categorie Soggetti
Pharmacology,"da verificare
Journal title
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
ISSN journal
0269-2813 → ACNP
Volume
15
Issue
9
Year of publication
2001
Pages
1331 - 1341
Database
ISI
SICI code
0269-2813(200109)15:9<1331:MOCDO1>2.0.ZU;2-A
Abstract
Background: It may be possible to achieve more effective management of Croh n's Disease by introducing a flexible dosage regimen sensitive to patients' needs. Aim: Comparison of the efficacy and tolerability of a fixed vs. flexible bu desonide controlled ileal release treatment regimen for the prevention and management of relapse in Crohn's disease patients. Budesonide controlled il eal release is an oral formulation which delivers drug directly to disease sites in the ileum and ascending colon, by preventing more proximal release and absorption. Methods: A randomized, double-blind comparison of a fixed dose of budesonid e controlled ileal release (6 mg o.m.) and a flexible dose of budesonide co ntrolled ileal release (3, 6 or 9 mg o.m.) for 12 months, in 143 patients i n remission from ileal or ileo-caecal Crohn's Disease. Results: Very low rates of clinical relapse in Crohn's disease were achieve d with budesonide controlled ileal release 6 mg o.m. There was no significa nt difference between the treatment groups with respect to the survival est imate of percentage of treatment failures (flexible group 15%, fixed group 19%; P = 0.61). The average consumed dose of budesonide was comparable in b oth groups (5.8 mg flexible, 6.0 mg fixed). Similar proportions of patients reported adverse events (flexible 100%, fixed 97%). There were 33 serious adverse events (flexible 19, fixed 14) and 13 withdrawals due to significan t adverse events (flexible 9, fixed 4). Conclusion: Maintenance treatment with budesonide controlled ileal release 6 mg o.m. is well-tolerated and is associated with low rates of clinical re lapse in stable Crohn's disease over 12 months. Flexible dosing remains an option for individual patients, but this study has shown no advantage over a standard fixed dosing regimen.